Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Diseases 1Urinary Retention 1Urinary Bladder Neoplasms 1Thrombocytopenia 1Prostatic Neoplasms 1Patient Satisfaction 1Neoplasms 1Hemostatic Disorders 1Hemorrhage 1Hematuria 1

Interventions

Gemcitabine 17pembrolizumab 16Cisplatin 14enfortumab vedotin 7avelumab 7Nivolumab 6Docetaxel 6atezolizumab 5Paclitaxel 5Cystectomy 5sacituzumab govitecan 4durvalumab 4Mitomycin 4Cystoscopy 4Carboplatin 4vofatamab 3tremelimumab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3vinflunine 2tisotumab vedotin 2poly ICLC 2cemiplimab 2aldesleukin 2Transurethral Resection of Bladder 2Radiotherapy, Intensity-Modulated 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Clinical Trials, Phase II as Topic 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Urinary Bladder Neoplasms × Tranexamic Acid × Clear all
NCT04555343 2021-11-05

Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention

Fraser Health

Phase 1/2 Completed
14 enrolled
Genitourinary

Urinary Bladder Neoplasms, Hematuria, Prostatic Neoplasms, Urologic Diseases, Urinary Retention, Patient Satisfaction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡